Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
AIDS related non-Hodgkin's lymphoma (NHL): the correlation between pre CD4 cell counts and the outcome of chemotherapy (Meeting abstract).
Proc Annu Meet Am Assoc Cancer Res; 14:A829 1995. Unique Identifier : AIDSLINE ICDB/95613981 Toi M; Caven G; Myers A; Kane M; Denver General Hospital (DGH), Denver, CO
Abstract:
Medical records of 37 patients with AIDS-related NHL (excluding CNS NHL) seen between 1983 and 1993 at either DGH, UCHSC, or VAMC, were reviewed. The following data were obtained: pre-treatment CD4 cell counts, patient sex, race, tumor stage, histologic classification, response to therapy, and survival. Also, the chemotherapy regimen used and the number of cycles administered, as well as, the occurrence of opportunistic infections before or after the initiation of chemotherapy were determined. Seven patients who did not receive chemotherapy were excluded. Fifteen patients had absolute CD4 cell counts above 100 cells pre-treatment (Group A). Fifteen had pretreatment absolute CD4 cell counts below 100 cells (Group B). There were 29 males and one female. Twenty-three were Caucasian, one African-American, and 6 Hispanic. A total of ten patients are alive with either no evidence of disease or are currently being treated (7 in Group A, 3 in Group B). The mean survival to date of these two patient groups was determined excluding the patients currently being treated. The mean survival of the patients in Group A was 366 days, and the patients in Group B was 184 days. The most commonly used chemotherapy regimens were modified m-BACOD and modified CHOP. However, there was no correlation between survival and the number of chemotherapy cycles administered. The mean number of chemotherapy cycles received was 3.2 for patients in Group A, and 3.1 for patients in Group B. Nine patients experienced the development of opportunistic infections (3 in group A, 6 in Group B). The occurrence of opportunistic infections was found to be more common in Group B, as expected. Our data also indicate that low CD4 cell counts did not significantly disrupt planned treatment schedules, but perhaps lessened the patient's likelihood of response to treatment and therefore their survival.
Keywords: Antineoplastic Agents, Combined/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/EPIDEMIOLOGY Biological Markers/BLOOD Bleomycin/ADMINISTRATION & DOSAGE Cyclophosphamide/ADMINISTRATION & DOSAGE *CD4 Lymphocyte Count Dexamethasone/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION & DOSAGE Female Human Leucovorin/ADMINISTRATION & DOSAGE Lymphoma, AIDS-Related/*DRUG THERAPY/*IMMUNOLOGY/MORTALITY Male Medical Records Methotrexate/ADMINISTRATION & DOSAGE Predictive Value of Tests Prednisone/ADMINISTRATION & DOSAGE Retrospective Studies Survival Rate Time Factors Treatment Outcome Vincristine/ADMINISTRATION & DOSAGE ABSTRACT 951230
M95C3208
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
